Nucleic Acid Ligands for Reversible GPVI Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and modulatable agents to specifically target and regulate the function of glycoprotein VI (GPVI), a key receptor involved in platelet activation and various disorders, including vascular diseases and inflammatory conditions.
Innovation Solution
Development of nucleic acid ligands that specifically bind to GPVI, along with modulators to reversibly control their activity, inhibiting GPVI-mediated platelet activation and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nucleic acid ligands are designed to specifically bind GPVI, then specificity and affinity for GPVI are improved, but the complexity of drug design and development increases
Solution Approach 1:
The patent uses nucleic acid ligands as intermediary molecules that specifically bind to GPVI through complementary base pairing and structural recognition. These ligands act as mediators between the therapeutic goal (inhibiting platelet activation) and the target (GPVI receptor), providing high specificity while simplifying the overall drug design approach compared to traditional small molecule inhibitors
Solution Approach 2:
The patent employs systematic variation of nucleic acid ligand parameters including sequence composition, length, secondary structure formation, and chemical modifications to optimize binding affinity and specificity for GPVI. By changing these parameters in a controlled manner, the patent achieves high specificity while maintaining manageable design complexity through iterative optimization
2Reliability
If irreversible inhibitors are used to block GPVI, then therapeutic efficacy is improved, but reversibility and control of pharmacologic effect are lost
Solution Approach 1:
The patent employs dynamic, reversible binding interactions between nucleic acid ligands and GPVI rather than irreversible covalent bonding. This allows the pharmacologic effect to be dynamically controlled - the ligand can bind to inhibit platelet activation when needed, and dissociate when the effect needs to be reversed, providing both efficacy and adaptability
Solution Approach 2:
The patent enables periodic administration and removal of the nucleic acid ligand to achieve desired therapeutic effects. The reversible binding allows for periodic inhibition of GPVI activity followed by restoration of normal function, providing controlled pharmacologic action that can be adjusted based on therapeutic needs
3Adaptability or versatility
If broad-spectrum platelet inhibitors are used, then coverage of platelet-mediated disorders is improved, but selectivity and potential side effects worsen
Solution Approach 1:
The patent targets the specific local structure of GPVI using nucleic acid ligands designed to recognize and bind to particular structural features of the GPVI receptor. This localized, structure-specific binding provides high selectivity for GPVI over other platelet receptors, achieving coverage of platelet-mediated disorders while minimizing side effects through precise molecular recognition
Solution Approach 2:
The patent demonstrates that the nucleic acid ligand approach can universally target GPVI across different platelet-mediated conditions including thrombosis, inflammation, and tumor metastasis. The same specific ligand design principle applies across multiple disease contexts, providing broad coverage while maintaining high selectivity for the GPVI target
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid ligands effectively inhibit GPVI activity, reducing platelet adhesion and aggregation, providing a therapeutic approach for platelet-mediated disorders with reversible pharmacologic control.
Implementation Method 1
nucleic acid ligands that specifically bind to GPVI
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.